CLASS II Drug recall · Reported 15 May 2019 · FDA Enforcement Report

Ketorolac Tromethamine Injection, USP, 60 mg recalled

Sagent Pharmaceuticals is recalling Ketorolac Tromethamine Injection, USP, 60 mg per (30 mg per mL) Vials, distributed nationwide in the US. The recall was initiated on 30 Apr 2019 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: M813513, Exp. Feb 2020
NDC25021-700, 25021-701
Quantity recalled75,825 vials

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1274-2019
FDA event ID
82741
Recalling firm
Sagent Pharmaceuticals, Schaumburg, IL
Manufacturer
Sagent Pharmaceuticals
Classification
Class II
Status
Terminated
Recall initiated
30 Apr 2019
FDA classified
9 May 2019
Reported
15 May 2019
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Sterility
Drug class
Pain Medication

Timeline

30 Apr 2019Recall initiated by company
9 May 2019Classified by FDA+9 days
15 May 2019Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Lack of Sterility Assurance: Microbial growth detected during a routine simulation of the manufacturing process, which represents the potential introduction of microorganisms into the products.

A sterility recall means a product that must be sterile, such as an injection or eye drop, may be contaminated. Using a non-sterile product can cause serious infection.

Product as listed by the FDA

Ketorolac Tromethamine Injection, USP, 60 mg per 2 mL (30 mg per mL), 2 mL Vials, Rx only, Mfd. for Sagent Pharmaceuticals, Schaumburg, IL 60195, NDC: 25021-701-02

Where it was distributed

Nationwide USA and Puerto Rico

Nationwide Puerto Rico

Questions about this recall

Is Ketorolac Tromethamine Injection, USP, 60 mg per (30 mg per mL) Vials recalled?

Yes. Sagent Pharmaceuticals recalled Ketorolac Tromethamine Injection, USP, 60 mg per (30 mg per mL) Vials on 30 Apr 2019. The recall is Class II and its status is Terminated. Recall number D-1274-2019.

Why was it recalled?

Lack of Sterility Assurance: Microbial growth detected during a routine simulation of the manufacturing process, which represents the potential introduction of microorganisms into the products.

Which lots are affected?

Lot #: M813513, Exp. Feb 2020

Where was it sold?

Nationwide USA and Puerto Rico

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Sagent Pharmaceuticals

All 23

Other Ketorolac Tromethamine recalls

All 19
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIKetorolac Tromethamine Injection, USP, 60 mg recalled by Aspiro PharmaKetorolac TromethamineAspiro PharmaParticulate MatterNationwide
DrugCLASS IIKetorolac Tromethamine Ophthalmic Solution recalled by ApotexKetorolac TromethamineApotexSterilityNationwide
DrugCLASS IIKetorolac Tromethamine Ophthalmic Solution recalled by ApotexKetorolac TromethamineApotexSterilityNationwide
DrugCLASS IIKetorolac Tromethamine Injection, USP 60 mg/ (30 mg/mL) recalledKetorolac TromethamineNephron ScManufacturing (CGMP) DeviationsNationwide
DrugCLASS IKetorolac Tromethamine Injection, USP, 30 mg per mL recalledKetorolac TromethamineFresenius Kabi USAParticulate MatterNationwide